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L E T T E R TO TH E ED I TOR
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in
25 patients with hematological malignancies who recovered
from SARS‐COV‐2 infection
Data on the dynamics and duration of humoral immune responses
against SARS‐CoV‐2 in hematological patients are still lacking. Pre-
liminary studies in non‐immunocompromised subjects with COVID‐
19 reported seroconversion 7 to 14 days following symptom onset,
with increased IgM and IgG titers observed during the first month.
IgM levels, after peaking by day 30, gradually decreased and were
undetectable by day 180. The long‐lasting persistence of IgG has not
been clearly demonstrated.1–5
We evaluated the humoral response and kinetics of IgM and IgG
against SARS‐CoV‐2 in 25 hematologic patients, receiving anticancer
therapy, who were followed after real‐time quantitative polymerase
chain reaction (RT‐qPCR) confirmation of SARS‐CoV‐2 infection. The
patient demographics and clinical characteristics are shown in Ta-
ble 1. The median age was 59 years (range 21–85). The underling
hematologic diseases were: lymphoma (10/25), myeloma (7/25),
chronic lymphoproliferative diseases (5/25) and acute leukemia
(3/25). SARS‐CoV‐2 infection was mild symptomatic in 5/25 (20%)
cases and symptomatic in 20/25 (80%), the most frequent symptoms
being fever, sore throat, anosmia, cough, shortness of breathing, and
fatigue. Four of the 20 symptomatic patients had pneumonia
requiring hospitalization. None of these 25 patients died from
COVID‐19.
The median IgG, IgM, and IgA values at SARS‐CoV‐2 infection
onset were 832 mg/dl (167–2210 mg/dl), 54.5 mg/dl (6–2510 mg/dl),
and 54 mg/dl (8–605 mg/dl), respectively. The median lymphocyte
count was 1100/mmc (250–3300/mmc).
The IgM and IgG antibodies against SARS‐CoV‐2 spike protein
(subunity S1 and S2) were tested by chemiluminescence immuno-
assay (CLIA) with a positive cut‐off value of 12 UA/ml for both IgG
and IgM. The specificity and sensibility of this assay was 98,5% and
97,4%, respectively.6 All patients signed written informed consent for
the serological test. To assess the kinetics of antibody titers, in our
convalescent COVID‐19 patients, serum IgM and IgG levels were
longitudinally measured at established time points: 1 month (T1) 2
months (T2), 3 months (T3), 4 months (T4) and 6 months (T6) after
their first positive nasopharyngeal swab test. None of these cases
received anti SARS‐CoV‐2 vaccination during the study period.
Among these 25 confirmed COVID‐19 cases, 21/25 (84%) devel-
oped specific anti SARS‐CoV‐2 antibodies with a titer > 12 UA/ml in
almost one of the specific time points. However, as reported in Figure 1
(A) and 1(B), after a peak of the IgG and an overall mild increase of IgM,
the antibody titer declined from 4 months after the disease onset
under the positive cut‐off value, although variation between patients
was detected. Themean andmedian titers were detailed in Figure 1(A)
and 1(B).
TAB L E 1 Characteristics of 25 Hematologic patients with
COVID‐19
No. of cases 25
Sex (M/F) 12/13
Median age‐years (range) 59 (21–85)
Hematologic malignancies
� Lymphoma 10/25 (40%)
� Myeloma 7/25 (28%)
� Chronic lymphoid leukemia (CLL) 5/25 (20%)
� Acute leukemia 3/25 (12%)
Concomitant therapy
� Chemotherapy (CHT) 10/25 (40%)
� Steroids 5/25 (20%)
� Rituximab ± CHT 4/25 (16%)
� Daratumomab ± CHT 4/25 (16%)
� Ibrutinib or venetoclax 3/25 (12%)
� Othera 2/25 (8%)
Immunoglobulins,b mg/dl‐ median (range)
� IgG 832 (167–2210)
� IgM 54,5 (6–2510)
� IgA 54 (8–605)
Lymphocytesb, N/mmc‐median (range) 1100 (250–3300)
a1 Nivolumab; 1 Ponatinib and prednisone.
bMedian values at SARS‐CoV‐2 infection onset.
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In summary, although we analyzed a limited number of cases,
patients with hematological malignancy appear to have an antibody
response to SARS‐CoV‐2 and a high rate of seroconversion (84%).
However, the kinetic of antibody levels may suggest that the duration
of antibody‐mediated protection against re‐infection with SARS‐
CoV‐2 may be short‐lasting.7,8 If confirmed in a larger number of
cases, these findings would suggest that stringent infection preven-
tion and control measures must be maintained in hematological pa-
tients who have recovered from COVID‐19. In addition, our results
would suggest that hematological patients could require a periodic
re‐vaccination. Obviously, additional studies of both humoral and
cellular immunity (T and memory B cells) will be necessary to better
understand the dynamics, duration, and intensity of the overall
immunological response to SARS‐CoV‐2 infection in hematological
malignancy patients.
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